Literature DB >> 7556619

Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site.

L P Wennogle1, H Liang, J C Quintavalla, B R Bowen, J Wasvary, D B Miller, A Allentoff, W Boyer, M Kelly, P Marshall.   

Abstract

The search for isoform-specific enzyme inhibitors has been the focus of much recent research effort. Towards this goal, human recombinant cyclooxygenase-2 (EC 1.14.99.1, prostaglandin H synthase) was expressed in insect cells and purified to > 98% purity. Recombinant enzyme was characterized both by physical methods and activity measurements and shown to be fully active with kinetic properties similar to native COX-2 and COX-1. After detergent extraction, the enzyme had hydrodynamic properties indistinguishable from native bovine COX-1 and corresponded to the enzyme dimer as measured with size-exclusion chromatography. Peptide mapping via Lys-C protease identified a site of N-linked glycosylation and the aspirin covalent modification site. In the presence of heme, aspirin-specifically acetylated Ser-516. The enzyme will be suitable for biophysical studies and may lead to isoform-specific enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556619     DOI: 10.1016/0014-5793(95)00930-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

Review 1.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

2.  Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways.

Authors:  Xinping Liu; Sung Ho Moon; Christopher M Jenkins; Harold F Sims; Richard W Gross
Journal:  Cell Chem Biol       Date:  2016-09-15       Impact factor: 8.116

3.  Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

Authors:  Ronald Esser; Carol Berry; Zhengming Du; Janet Dawson; Alyson Fox; Roger A Fujimoto; William Haston; Earl F Kimble; Julie Koehler; Jane Peppard; Elizabeth Quadros; Joseph Quintavalla; Karen Toscano; Laszlo Urban; John van Duzer; Xiaoli Zhang; Siyuan Zhou; Paul J Marshall
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.

Authors:  Joel D Maust; Christy L Frankowski-McGregor; Armand Bankhead; Diane M Simeone; Judith S Sebolt-Leopold
Journal:  Mol Cancer Ther       Date:  2018-09-25       Impact factor: 6.261

Review 5.  Bystander signaling via oxidative metabolism.

Authors:  Humaira Aziz Sawal; Kashif Asghar; Matthias Bureik; Nasir Jalal
Journal:  Onco Targets Ther       Date:  2017-08-04       Impact factor: 4.147

6.  The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer.

Authors:  Maoyi Xu; Binbin Song; Xinmei Yang; Na Li
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.